<br>Gαs-蛋白激酶 A (PKA) 通路信号传导：异常 Gαs-PKA 信号传导驱动的新兴遗传景观和人类疾病的治疗潜力,Pharmacological Reviews

当前位置： X-MOL 学术 › Pharmacol. Rev. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Gαs-蛋白激酶 A (PKA) 通路信号传导：异常 Gαs-PKA 信号传导驱动的新兴遗传景观和人类疾病的治疗潜力
Pharmacological Reviews ( IF 19.3 ) Pub Date : 2021-10-01 , DOI: 10.1124/pharmrev.120.000269
Dana J Ramms ₁ , Francesco Raimondi ₁ , Nadia Arang ₁ , Friedrich W Herberg ₁ , Susan S Taylor ₁ , J Silvio Gutkind ₂

Affiliation

信号转导和激酶活性的许多基本概念都归因于 cAMP 依赖性蛋白激酶或蛋白激酶 A 的发现和结晶。PKA 是人类生物学中研究最深入的激酶之一，重点是生物化学和生物物理学，一直到新陈代谢、激素作用和基因表达调节。然而，令人惊讶的是，我们对 PKA 在疾病中的作用的理解在很大程度上被低估了。尽管已知 PKA 全酶的基因突变会导致卡尼复合体、库欣综合征和肢端骨质疏松症等疾病，但故事基本上到此为止。随着最近基因组医学的爆炸式增长，我们终于可以认识到 G α s-PKA 通路在疾病中的更广泛作用，其中包括功能异常的 G 蛋白和 G 蛋白偶联受体，以及其他通路成分的多重改变和负调节器。这些疾病共同代表了一个广泛的疾病家族，我们将其称为 G α s-PKA 通路信号病。 G α s-PKA 途径信号病包括由 G α s-PKA 途径种系、合子后和体细胞突变引起的疾病，主要是内分泌和肿瘤表型。在这里，我们对 G α s-PKA 驱动的病理生理学进行了以信号传导为中心的综述，并整合计算和结构分析来识别 G α s-PKA 途径信号病变通常利用的突变主题。主要突变主题包括GNAS 编码的 Gα 热点激活突变，以及破坏 PKA 全酶稳定性的突变。通过这次综述，我们希望激发进一步的研究，并最终开发出治疗多种人类疾病的新治疗策略。

"点击查看英文标题和摘要"

Gαs–Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant Gαs-PKA Signaling

Many of the fundamental concepts of signal transduction and kinase activity are attributed to the discovery and crystallization of cAMP-dependent protein kinase, or protein kinase A. PKA is one of the best-studied kinases in human biology, with emphasis in biochemistry and biophysics, all the way to metabolism, hormone action, and gene expression regulation. It is surprising, however, that our understanding of PKA’s role in disease is largely underappreciated. Although genetic mutations in the PKA holoenzyme are known to cause diseases such as Carney complex, Cushing syndrome, and acrodysostosis, the story largely stops there. With the recent explosion of genomic medicine, we can finally appreciate the broader role of the Gαs-PKA pathway in disease, with contributions from aberrant functioning G proteins and G protein–coupled receptors, as well as multiple alterations in other pathway components and negative regulators. Together, these represent a broad family of diseases we term the Gαs-PKA pathway signalopathies. The Gαs-PKA pathway signalopathies encompass diseases caused by germline, postzygotic, and somatic mutations in the Gαs-PKA pathway, with largely endocrine and neoplastic phenotypes. Here, we present a signaling-centric review of Gαs-PKA–driven pathophysiology and integrate computational and structural analysis to identify mutational themes commonly exploited by the Gαs-PKA pathway signalopathies. Major mutational themes include hotspot activating mutations in Gαs, encoded by GNAS, and mutations that destabilize the PKA holoenzyme. With this review, we hope to incite further study and ultimately the development of new therapeutic strategies in the treatment of a wide range of human diseases.

更新日期：2021-10-18

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11